Risperdal
Generalized Anxiety Disorder
University of South FloridaPhase 4 / ApprovedDormant
BB
68/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 53/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Generalized Anxiety Disorder cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Seroquel® Icahn School of Medicine at Mount Sinai | Phase 4 | BBB |
ZIPRASIDONE VA Palo Alto Health Care System | Phase 4 | BB |
Acamprosate Medical University of South Carolina | Phase 4 | BB |
Valproic Acid University of South Florida | Phase 4 | BB |
Paroxetine Beijing Tongren Hospital | Phase 1 | CC |
Duloxetine | D | |
Isoproterenol Laureate Institute for Brain Research, Inc. | N/A | D |
Abbv-932 AbbVie | Phase 1 | NR |
Same molecule, other indications
Risperdal is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →